📊 PRCT Key Takeaways
Is PROCEPT BioRobotics Corp (PRCT) a Good Investment?
PROCEPT demonstrates impressive revenue growth (+37.2% YoY) and exceptional gross margins (63.7%), indicating strong product-market fit in surgical robotics. However, the company is unprofitable at scale with operating losses exceeding $100M annually and negative free cash flow of $58.3M, creating significant financial headwinds despite a strong cash position that provides ~4-5 years of runway.
Why Buy PROCEPT BioRobotics Corp Stock? PRCT Key Strengths
- Strong revenue growth of 37.2% YoY indicates robust market demand for surgical robotics
- Exceptional gross margins of 63.7% demonstrate pricing power and product viability
- Fortress balance sheet with $286.5M cash, 6.85x current ratio, and minimal debt (0.14x leverage)
PRCT Stock Risks: PROCEPT BioRobotics Corp Investment Risks
- Operating losses of $103.9M annually with -33.7% operating margin despite revenue scale
- Negative free cash flow of $58.3M annually indicating cash burn even as revenue grows
- Unclear path to profitability; losses are deteriorating in absolute terms despite improving EPS metrics
Key Metrics to Watch
- Operating margin trend toward breakeven
- Free cash flow inflection point and timeline to positive FCF
- Gross margin sustainability as manufacturing scales
PROCEPT BioRobotics Corp (PRCT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.85x current ratio provides a solid financial cushion.
PRCT Profit Margin, ROE & Profitability Analysis
PRCT vs Healthcare Sector: How PROCEPT BioRobotics Corp Compares
How PROCEPT BioRobotics Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is PROCEPT BioRobotics Corp Stock Overvalued? PRCT Valuation Analysis 2026
Based on fundamental analysis, PROCEPT BioRobotics Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
PROCEPT BioRobotics Corp Balance Sheet: PRCT Debt, Cash & Liquidity
PRCT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: PROCEPT BioRobotics Corp's revenue has grown significantly by 794% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.24 indicates the company is currently unprofitable.
PRCT Revenue Growth, EPS Growth & YoY Performance
PRCT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $58.4M | -$19.6M | $-0.38 |
| Q2 2025 | $53.4M | -$19.6M | $-0.35 |
| Q1 2025 | $44.5M | -$24.7M | $-0.45 |
| Q3 2024 | $35.1M | -$21.0M | $-0.40 |
| Q2 2024 | $33.1M | -$25.3M | $-0.50 |
| Q1 2024 | $24.4M | -$26.0M | $-0.51 |
| Q3 2023 | $20.3M | -$17.2M | $-0.51 |
| Q2 2023 | $16.7M | -$17.2M | $-0.43 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
PROCEPT BioRobotics Corp Dividends, Buybacks & Capital Allocation
PRCT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for PROCEPT BioRobotics Corp (CIK: 0001588978)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PRCT
What is the AI rating for PRCT?
PROCEPT BioRobotics Corp (PRCT) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PRCT's key strengths?
Claude: Strong revenue growth of 37.2% YoY indicates robust market demand for surgical robotics. Exceptional gross margins of 63.7% demonstrate pricing power and product viability.
What are the risks of investing in PRCT?
Claude: Operating losses of $103.9M annually with -33.7% operating margin despite revenue scale. Negative free cash flow of $58.3M annually indicating cash burn even as revenue grows.
What is PRCT's revenue and growth?
PROCEPT BioRobotics Corp reported revenue of $308.1M.
Does PRCT pay dividends?
PROCEPT BioRobotics Corp does not currently pay dividends.
Where can I find PRCT SEC filings?
Official SEC filings for PROCEPT BioRobotics Corp (CIK: 0001588978) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PRCT's EPS?
PROCEPT BioRobotics Corp has a diluted EPS of $-1.72.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PRCT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, PROCEPT BioRobotics Corp has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PRCT stock overvalued or undervalued?
Valuation metrics for PRCT: ROE of -26.1% (sector avg: 15%), net margin of -31.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PRCT stock in 2026?
Our dual AI analysis gives PROCEPT BioRobotics Corp a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PRCT's free cash flow?
PROCEPT BioRobotics Corp's operating cash flow is $-49.0M, with capital expenditures of $9.4M. FCF margin is -18.9%.
How does PRCT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -31.0% (avg: 12%), ROE -26.1% (avg: 15%), current ratio 6.85 (avg: 2).